Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Hep C Discussion Forum -> Hep C News -> Sovaldi/Olysio Survey Data
Post Info TOPIC: Sovaldi/Olysio Survey Data
Matt Chris


Guru

Status: Offline
Posts: 1781
Date:
RE: Sovaldi/Olysio Survey Data
Permalink  
 

Hey Wayne & Tig

J&J will have to pair up with another DAA to make it appeal to the US customers once Gilead's combo is released. They could moderate the price but most people in the US will want the best Meds. The third world markets and other countries offer a lot more marketing opportunities with a lower price. 

It feels like Gilead's Sovaldi will have to make some kind of adjustment in their price with all the attention they are getting from the Federal and State agencies. I suspect that when their new combo gets approved that it will be the new $1,000 pill and Sovaldi will be reduced or somehow discounted via special programs.

These pressures from all sides will make Gilead both squirm and profitable.

matt



__________________

"And in the end, the love you take is equal to the love you make"

61 year old Geno type A1, F4 Cirrhotic, started 24 weeks on Harvoni 12-17-14 ,EOT-5 week = UND, 8-31-15 =UND , SVR-24 Baby YES! 
OldenSlow


Senior Member

Status: Offline
Posts: 380
Date:
Permalink  
 

Tig,

I'd like to believe in more egalitarian business models. J&J knows they can't sustain the current Olysio price much longer. They'll be looking at more than one set of tail lights. I suspect they will strive to maximize profit while they can. 

wayne



__________________

66 y/o male - Geno 1b - F4 cirrhotic dx 2001 - 16 wk treatment w/ Sovaldi/Olysio/Riba - Und @ EOT+24 SVR

 
Tig


Admin

Status: Offline
Posts: 9270
Date:
Permalink  
 

Hi Wayne,

That's an interesting article. I see Olysio is going to have quite an uphill battle against Sovaldi for market share. I believe they could regain some ground by lowering their introductory costs and improve their customer relations. It won't be long and Ledispavir will be available and all JnJ will see is Gilead's tail lights!

Tig



__________________

Tig

67yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 9+ years!

Hep C FAQ   Lab Ref. Ranges  HCV Resistance

Signature Line Set Up/Abbreviations   Payment Assistance

 
OldenSlow


Senior Member

Status: Offline
Posts: 380
Date:
Permalink  
 

From the Decision Resources Group    March 19, 2014

"Cost is the leading prescribing barrier for both Olysio and Sovaldi. Although most surveyed prescribers did not indicate major payer obstacles, many non-prescribers reported experiencing reimbursement obstacles, suggesting that reimbursement is a barrier to prescribing."

Article:

http://hepatitiscnewdrugs.blogspot.com/2014/03/hepatitis-c-sovaldi-based-regimens-will.html



-- Edited by OldenSlow on Thursday 20th of March 2014 07:42:13 PM

__________________

66 y/o male - Geno 1b - F4 cirrhotic dx 2001 - 16 wk treatment w/ Sovaldi/Olysio/Riba - Und @ EOT+24 SVR

 
Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.
Hep C Discussion Forum -> Hep C News -> Sovaldi/Olysio Survey Data
Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.